Robert Forgan Halenbeck is a notable inventor based in San Francisco, CA. He has made significant contributions to the field of medical research, particularly in the development of treatments for various diseases. With a total of 2 patents, Halenbeck's work focuses on innovative solutions that address critical health challenges.

Latest Patents

Halenbeck's latest patents include compositions and methods of use for monocyte, granulocyte, and dendritic cell colony stimulating factor (MGD-CSF) in disease treatment. This newly identified secreted molecule has a polypeptide sequence and polynucleotides encoding the sequence. The patent also outlines a procedure for producing the polypeptide using recombinant techniques, including vectors and host cells. Furthermore, it describes methods for modifying these novel molecules to create fusion molecules. The applications of these polypeptides and their active fragments are aimed at treating a variety of diseases, such as cancer, autoimmune and inflammatory diseases, infectious diseases, and recurrent pregnancy loss.

Career Highlights

Halenbeck is currently associated with Five Prime Therapeutics, Inc., where he continues to advance his research and innovations. His work has the potential to significantly impact the medical field and improve patient outcomes.

Collaborations

Halenbeck collaborates with esteemed colleagues, including Dirk Behrens and Elizabeth Bosch, to further enhance the scope and effectiveness of his research.

Conclusion

Robert Forgan Halenbeck is a dedicated inventor whose work in the field of disease treatment showcases his commitment to innovation and improving healthcare. His contributions are paving the way for new therapeutic approaches that could benefit many patients in need.

This text is generated by artificial intelligence and may not be accurate.